Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported.Objective. To assess efficacy and safety of anti-VEGF/...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-06-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6206 |